Regeneron Pharmaceuticals Surges to 109th in Trading Volume with $672 Million in Shares Exchanged Amid 23andMe Acquisition

On May 20, 2025, Regeneron Pharmaceuticals (REGN) saw a significant surge in trading volume, with a total of $672 million in shares exchanged, marking a 69.79% increase from the previous day. This surge placed Regeneron at the 109th position in terms of trading volume for the day. The stock price also rose by 3.06%, extending its winning streak to four consecutive days, with a total gain of 7.60% over the past four days.

Regeneron Pharmaceuticals has announced its acquisition of 23andMe, a genetic testing company, for $256 million through a bankruptcy auction. This acquisition includes substantially all of 23andMe's assets, excluding its telehealth subsidiary, Lemonaid Health, which will be shut down. The deal is subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri and is expected to close in the third quarter of this year.

Regeneron's acquisition of 23andMe is part of its strategy to enhance its capabilities in genetic testing and personal health data. The company aims to leverage 23andMe's Personal Genome Service, Total Health, and Research Services business lines to further its mission of improving health and wellness. Regeneron has also committed to prioritizing the privacy, security, and ethical use of 23andMe's customer data, addressing concerns raised by lawmakers and officials regarding the safety of consumers' genetic data.

23andMe, once a high-flying genetic testing company, faced challenges in generating recurring revenue and building viable research and therapeutics businesses after going public in 2021. The company's bankruptcy proceedings required all bidders to comply with its privacy policies, and a court-appointed, independent "Consumer Privacy Ombudsman" will assess the deal. The ombudsman will present a report on the acquisition to the court by June 10, ensuring that customer privacy, choice, and consent are maintained.